The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection
…, H Christensen, R Debbag, P De Wals… - Expert review of …, 2017 - Taylor & Francis
… P De Wals has received research grants and reimbursements of travel expenses from vaccine
manufacturers including GlaxoSmithKline, Novartis, Sanofi Pasteur, and Pfizer, as well as …
manufacturers including GlaxoSmithKline, Novartis, Sanofi Pasteur, and Pfizer, as well as …
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic …
…, H Christensen, Y Climent, P De Wals… - Expert review of …, 2019 - Taylor & Francis
… P. De Wals has received research grants, and reimbursements of travel expenses from
vaccine manufacturers including GSK, Novartis, Sanofi Pasteur, and Pfizer, as well as from …
vaccine manufacturers including GSK, Novartis, Sanofi Pasteur, and Pfizer, as well as from …
The burden of childhood pneumonia in the developed world: a review of the literature
SA Madhi, P De Wals, CG Grijalva… - The Pediatric …, 2013 - journals.lww.com
Background: Estimates of the disease burden from childhood pneumonia are available for
most developed countries, but they are based mainly on models. Measured country-specific …
most developed countries, but they are based mainly on models. Measured country-specific …
[HTML][HTML] Reduction in neural-tube defects after folic acid fortification in Canada
P De Wals, F Tairou, MI Van Allen, SH Uh… - … England Journal of …, 2007 - Mass Medical Soc
Background In 1998, folic acid fortification of a large variety of cereal products became
mandatory in Canada, a country where the prevalence of neural-tube defects was historically …
mandatory in Canada, a country where the prevalence of neural-tube defects was historically …
[HTML][HTML] Protection against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron SARS-CoV-2 infection among health-care …
…, G Deceuninck, P De Wals, G De Serres - The Lancet Infectious …, 2023 - thelancet.com
… Prof Philippe De Wals, PhD Philippe De Wals … Avis portant sur la pertinence d'une dose
additionnelle de vaccin contre la COVDI-19 pour les personnes ayant une immunodépression. …
additionnelle de vaccin contre la COVDI-19 pour les personnes ayant une immunodépression. …
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec …
…, M Naus, DM Patrick, B Henry, LMN Hoang, P De Wals… - MedRxiv, 2021 - medrxiv.org
Background The Canadian COVID-19 immunization strategy deferred second doses and
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
An analytical framework for immunization programs in Canada
LJ Erickson, P De Wals, L Farand - Vaccine, 2005 - Elsevier
Recent years have seen an increase in the number of new vaccines available on the Canadian
market, and increasing divergence in provincial and territorial immunization programs as …
market, and increasing divergence in provincial and territorial immunization programs as …
Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNA–vaccinated and nonvaccinated individuals in …
…, A Carignan, P De Wals, G De Serres - JAMA network …, 2022 - jamanetwork.com
Importance The Omicron variant is phylogenetically and antigenically distinct from earlier
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994
L Erickson, P De Wals - Reviews of Infectious Diseases, 1998 - academic.oup.com
… The authors thank the Laboratoire de Santé Publique du Québec The most striking finding
of this study is the high frequency and the participating regional health boards and hospitals. …
of this study is the high frequency and the participating regional health boards and hospitals. …
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
M Brisson, N Van de Velde, P De Wals, MC Boily - Vaccine, 2007 - Elsevier
… Brisson M, Van de Velde N, Boily MC, De Wals P. Estimating the number needed to vaccinate
to prevent human papillomavirus related disease and mortality, submitted for publication. …
to prevent human papillomavirus related disease and mortality, submitted for publication. …